Enzo BioChem posts $10.3M quarterly loss
Enzo BioChem Inc., Manhattan
Biotechnology developer; parent company of Enzo Clinical Labs, of Farmingdale
Second Quarter: Ended Jan. 31
Net revenue: Rose to $23.2 million from $21 million in the year-ago quarter.
Net income: Loss of $10.3 million, compared to a loss of $7.7 million in the same quarter last year.
Company statement: "The fiscal second quarter reflected another quarter of improved operating results, excluding unusually high proxy-related costs and a one-time payment to a former officer to settle litigation and the related legal costs," Barry Weiner, the company president, said in a statement. "Margin improvement reflected a more favorable mix of products at Enzo Life Sciences and a higher percentage of esoteric testing at Enzo Clinical Labs."
Sarra Sounds Off Ep. 35: EI baseball, girls lacrosse and plays of the week On the latest episode of "Sarra Sounds Off," we look at East Islip baseball's inspirational comeback story, Jared Valluzzi has the plays of the week and Tess Ferguson breaks down the top defensive players in girls lacrosse.
Sarra Sounds Off Ep. 35: EI baseball, girls lacrosse and plays of the week On the latest episode of "Sarra Sounds Off," we look at East Islip baseball's inspirational comeback story, Jared Valluzzi has the plays of the week and Tess Ferguson breaks down the top defensive players in girls lacrosse.
